Phase III randomized evaluation of 13-cis-retinoic acid (cRA) [isotretinoin] plus procarbazine versus procarbazine alone in the treatment of patients with recurrent primary malignant gliomas.

Trial Profile

Phase III randomized evaluation of 13-cis-retinoic acid (cRA) [isotretinoin] plus procarbazine versus procarbazine alone in the treatment of patients with recurrent primary malignant gliomas.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 21 Feb 2012

At a glance

  • Drugs Isotretinoin (Primary) ; Procarbazine (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Sep 2010 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 20 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top